Predicting Recurrence and Progression in Contemporary Patients with NMIBC Undergoing Blue Light Cystoscopy-Aided Transurethral Resection of Bladder Tumor.

Authors

Agustin Perez-Londoño, Jamil Almohtasib, Sumedh Kaul, Aaron Fleishman, Badrinath Konety, Kamal Pohar, Jeffrey M Holzbeierlein, John Taylor, Max Kates, Brian Willard, Jennifer M Taylor, Joseph C Liao, Hristos Z Kaimakliotis, Sima P Porten, Gary D Steinberg, Mark D Tyson, Yair Lotan, Siamak Daneshmand, Boris Gershman

Published in

Urology practice. Pages 101097UPJ0000000000001103. Oct 05, 2026. Epub Oct 05, 2026.

Abstract

Although blue light cystoscopy (BLC) is recommended by clinical practice guidelines to improve cancer detection, predictive models for patients undergoing BLC are lacking. We therefore evaluated the associations of clinicopathologic features with recurrence and progression in a contemporary cohort of patients treated with BLC to develop a risk prediction model.
We identified patients aged 18-89 years in the multi-institutional Blue Light Cystoscopy with Cysview Registry who underwent BLC-aided TURBT between 2014-2023. Associations of baseline characteristics with recurrence and progression were evaluated using Cox regression, and predictive models were developed using lasso regression.
1040 patients underwent BLC-TURBT. Tumor stage was Ta in 578 (56%), T1 in 166 (16%), and pure CIS in 190 (18%) patients. On multivariable analysis, HGTa (HR 1.60, 95%CI 1.10-2.35) and HGT1 (HR 1.94, 95%CI 1.25-3.02) tumors were associated with increased risk of recurrence. HGT1 (HR 12.4, 95%CI 4.52-34.0), HGTa (HR 3.08, 95% CI 1.03-9.18), pure CIS (HR 4.51, 95% CI 1.44-14.1), Ta+CIS (HR 4.98, 95%CI 1.17-21.1), and T1+CIS (HR 7.65, 95%CI 1.97-29.7) tumors, as well as lymphovascular invasion (HR 3.27, 95%CI 1.22-8.83) were associated with increased risk of progression. In contrast, adjuvant BCG was associated with decreased risk of progression (HR 0.40, 95%CI 0.22-0.72). Model discrimination was 0.64 for RFS and 0.73 for PFS.
Using a multi-institutional cohort, we developed predictive models for recurrence and progression in patients undergoing BLC-TURBT. Although they require external validation, these models reflect to contemporary treatment paradigms and can inform personalized, risk-adapted management of NMIBC.

PMID:
42832769
Bibliographic data and abstract were imported from PubMed on 06 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.